Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Teva Pharmaceutical to Replace CEO Kare Schultz

Teva Pharmaceutical to Replace CEO Kare Schultz

-Wall Street Journal

byCharles Gross

November 3, 2022

1 minute read

-Wall Street Journal

Morgan Stanley Maintains Overweight on CrowdStrike Holdings, Lowers Price Target to $190

By Benzinga Newsdesk

November 22, 9:38 AM

Morgan Stanley analyst Hamza Fodderwala maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Overweight and lowers the price target from $217 to $190.

CRWD

Rosenblatt Maintains Buy on Liberty Broadband, Lowers Price Target to $132

By Benzinga Newsdesk

February 24, 8:17 AM

Rosenblatt analyst Barton Crockett maintains Liberty Broadband (NASDAQ:LBRDK) with a Buy and lowers the price target from $133 to $132.

LBRDK

Why Texas Instruments Shares Are Sliding After Hours

By Adam Eckert

April 25, 4:28 PM

Texas Instruments Inc (NASDAQ: TXN) shares are trading lower in Tuesday's after-hours session after the company reported mixed first-quarter results and

TXN

Immutep H1 EPS A$(0.0236) Down From A$(0.0194) YoY, Sales A$2.58M Down From A$2.85M YoY

By Benzinga Newsdesk

February 24, 5:52 AM

Immutep (NASDAQ:IMMP) reported quarterly losses of A$(0.0236) per share. This is a 26.32 percent decrease over losses of A$(0.0194) per share from the same period last year. The company reported A$2.58 million in sales

IMMP

Teva Pharmaceutical to Replace CEO Kare Schultz

Related Posts

Morgan Stanley Maintains Overweight on CrowdStrike Holdings, Lowers Price Target to $190

Rosenblatt Maintains Buy on Liberty Broadband, Lowers Price Target to $132

Why Texas Instruments Shares Are Sliding After Hours

Immutep H1 EPS A$(0.0236) Down From A$(0.0194) YoY, Sales A$2.58M Down From A$2.85M YoY